{"protocolSection": {"identificationModule": {"nctId": "NCT01590771", "orgStudyIdInfo": {"id": "0431-253"}, "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)", "officialTitle": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy, Alone or in Combination With Metformin"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-07-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2014-06-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-06-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-05-01", "studyFirstSubmitQcDate": "2012-05-02", "studyFirstPostDateStruct": {"date": "2012-05-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-04-16", "resultsFirstSubmitQcDate": "2015-04-16", "resultsFirstPostDateStruct": {"date": "2015-05-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-07-20", "lastUpdatePostDateStruct": {"date": "2018-08-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable sulfonylurea alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis of this study is that after 24 weeks, the addition of sitagliptin compared with placebo provides greater reduction in hemoglobin A1C (HbA1C) in T2DM participants on sulfonylurea alone or in combination with metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 498, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during run-in period.", "interventionNames": ["Drug: Sitagliptin", "Drug: Gliclazide", "Drug: Glimepiride", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study.", "interventionNames": ["Drug: Placebo", "Drug: Gliclazide", "Drug: Glimepiride", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin 100 mg oral tablet once daily for 24 weeks", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia\u00ae", "MK-0431"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo to sitagliptin oral tablet once daily for 24 weeks", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Gliclazide", "description": "Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.", "armGroupLabels": ["Placebo", "Sitagliptin"]}, {"type": "DRUG", "name": "Glimepiride", "description": "Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.", "armGroupLabels": ["Placebo", "Sitagliptin"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.", "armGroupLabels": ["Placebo", "Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin", "description": "A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Number of Participants Who Experienced an Adverse Event", "description": "An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.", "timeFrame": "Up to 26 weeks"}, {"measure": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "description": "An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.", "timeFrame": "Up to 24 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin", "description": "This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin", "description": "This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin", "description": "A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone", "description": "A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin", "description": "This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone", "description": "This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin", "description": "This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone", "description": "This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* has T2DM\n* is currently on a stable regimen of gliclazide or glimepiride, either alone or in combination with metformin for \u2265 10 weeks\n* has a Visit 1/Screening HbA1C between 7.5% and 11.0%\n* is a male, or a female who is highly unlikely to conceive during the study and for 14 days after the last dose of study medication\n\nExclusion Criteria:\n\n* has a history of type 1 diabetes mellitus or a history of ketoacidosis\n* has been treated with any antihyperglycemic therapies other than a sulfonylurea (alone or with metformin) within the prior 12 weeks or has ever\n\nbeen treated with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 mimetic or analogue\n\n* has a history of intolerance or hypersensitivity, or has any contraindication to sitagliptin, gliclazide/glimepiride, or metformin\n* is on a weight loss program and not in the maintenance phase, or has started a weight loss medication or has undergone bariatric surgery within 12 months\n* has undergone a surgical procedure within 4 weeks or has planned major surgery during the study\n* has a medical history of active liver disease\n* has had new or worsening signs or symptoms of coronary heart disease within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder\n* has a diagnosis of congestive heart failure with New York Heart Association Class III - IV cardiac status\n* has a systolic blood pressure \u2265 160 mmHg or a diastolic blood pressure \u2265 90 mmHg\n* has human immunodeficiency virus (HIV)\n* has severe peripheral vascular disease\n* is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks\n* has a history of malignancy \u2264 5 years before the study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* has a clinically important hematological disorder (such as aplastic anemia,\n\nmyeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n* is pregnant or breast feeding, or is expecting to conceive or donate eggs during the study, including 14 days after the last dose of study medication\n* is a user of recreational or illicit drugs or has had a recent history of drug abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "referencesModule": {"references": [{"pmid": "27502307", "type": "RESULT", "citation": "Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes. 2017 Jul;9(7):667-676. doi: 10.1111/1753-0407.12456. Epub 2016 Sep 13."}], "availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=0431-253&kw=0431-253&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "All participants randomized population.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "FG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "249"}, {"groupId": "FG001", "numSubjects": "249"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "230"}, {"groupId": "FG001", "numSubjects": "210"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "39"}]}], "dropWithdraws": [{"type": "Other Protocol Specified Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "BG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "249"}, {"groupId": "BG001", "value": "249"}, {"groupId": "BG002", "value": "498"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.5", "spread": "9.5"}, {"groupId": "BG001", "value": "56.5", "spread": "9.3"}, {"groupId": "BG002", "value": "57.0", "spread": "9.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "132"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "249"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "117"}, {"groupId": "BG001", "value": "132"}, {"groupId": "BG002", "value": "249"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent of glycosylated hemoglobin (A1C)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.61", "spread": "1.06"}, {"groupId": "BG001", "value": "8.48", "spread": "0.91"}, {"groupId": "BG002", "value": "8.55", "spread": "0.99"}]}]}]}, {"title": "2-hour post meal glucose (2-hr PMG)", "description": "Sitagliptin, n=248; placebo, n=249; total, n=497", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "296.5", "spread": "68.0"}, {"groupId": "BG001", "value": "290.2", "spread": "72.4"}, {"groupId": "BG002", "value": "293.4", "spread": "70.2"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "description": "Sitagliptin, n=249; placebo, n=249; total, n=498", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "181.5", "spread": "40.9"}, {"groupId": "BG001", "value": "179.8", "spread": "40.7"}, {"groupId": "BG002", "value": "180.6", "spread": "40.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin", "description": "A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.", "populationDescription": "Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of glycosylated hemoglobin (A1C)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "243"}, {"groupId": "OG001", "value": "236"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.88", "lowerLimit": "-0.99", "upperLimit": "-0.76"}, {"groupId": "OG001", "value": "-0.27", "lowerLimit": "-0.38", "upperLimit": "-0.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "The ANCOVA model controlled for treatment, metformin strata (on or not on metformin), and baseline A1C value.", "statisticalMethod": "ANCOVA", "paramType": "Robust regression", "paramValue": "-0.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.77", "ciUpperLimit": "-0.44", "estimateComment": "Based on robust regression using M-estimation with terms for treatment, metformin strata (on or not on metformin), and baseline A1C value."}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin", "description": "This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.", "populationDescription": "Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "231"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-40.7", "lowerLimit": "-49.4", "upperLimit": "-31.9"}, {"groupId": "OG001", "value": "-7.7", "lowerLimit": "-16.6", "upperLimit": "1.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "The ANCOVA model controlled for treatment, metformin strata (on or not on metformin), and baseline 2-hr PMG value.", "statisticalMethod": "ANCOVA", "paramType": "Difference in least squares mean", "paramValue": "-32.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-45.4", "ciUpperLimit": "-20.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin", "description": "This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.", "populationDescription": "Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "246"}, {"groupId": "OG001", "value": "243"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-24.4", "spread": "-29.1", "lowerLimit": "-29.1", "upperLimit": "-19.8"}, {"groupId": "OG001", "value": "-7.7", "lowerLimit": "-12.3", "upperLimit": "-3.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Based on robust regression using M-estimation with terms for treatment, metformin strata (on or not on metformin), and baseline FPG value.", "statisticalMethod": "Robust regression", "paramType": "Estimate difference", "paramValue": "-16.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.3", "ciUpperLimit": "-10.2"}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin", "description": "A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.", "populationDescription": "Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of glycosylated hemoglobin (A1C)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "lowerLimit": "-1.01", "upperLimit": "-0.71"}, {"groupId": "OG001", "value": "-0.45", "lowerLimit": "-0.60", "upperLimit": "-0.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "The ANCOVA model controlled for treatment and baseline A1C value.", "statisticalMethod": "ANCOVA", "paramType": "Difference in least squares mean", "paramValue": "-0.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "-0.20"}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone", "description": "A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.", "populationDescription": "Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of glycosylated hemoglobin (A1C)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.85", "lowerLimit": "-1.04", "upperLimit": "-0.67"}, {"groupId": "OG001", "value": "-0.05", "lowerLimit": "-0.24", "upperLimit": "0.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "The ANCOVA model controlled for treatment and baseline A1C value.", "statisticalMethod": "ANCOVA", "paramType": "Difference in least squares mean", "paramValue": "-0.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.07", "ciUpperLimit": "-0.53"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin", "description": "This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.", "populationDescription": "Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-33.4", "lowerLimit": "-43.4", "upperLimit": "-23.5"}, {"groupId": "OG001", "value": "-6.2", "lowerLimit": "-16.1", "upperLimit": "3.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Based on robust regression using M-estimation with terms for treatment and baseline 2-hr PMG value.", "statisticalMethod": "Robust regression", "paramType": "Estimate difference", "paramValue": "-27.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-41.2", "ciUpperLimit": "-13.2"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone", "description": "This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.", "populationDescription": "Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-49.5", "lowerLimit": "-62.9", "upperLimit": "-36.2"}, {"groupId": "OG001", "value": "-11.9", "lowerLimit": "-25.8", "upperLimit": "2.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "The ANCOVA model controlled for treatment and baseline 2-hr PMG value.", "statisticalMethod": "ANCOVA", "paramType": "Difference in least squares mean", "paramValue": "-37.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-56.9", "ciUpperLimit": "-18.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin", "description": "This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.", "populationDescription": "Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.2", "lowerLimit": "-28.4", "upperLimit": "-16.0"}, {"groupId": "OG001", "value": "-5.7", "lowerLimit": "-11.9", "upperLimit": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Based on robust regression using M-estimation with terms for treatment and baseline FPG value.", "statisticalMethod": "Robust Regression", "paramType": "Estimate Difference", "paramValue": "-16.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.3", "ciUpperLimit": "-7.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone", "description": "This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.", "populationDescription": "Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-26.3", "lowerLimit": "-33.3", "upperLimit": "-19.4"}, {"groupId": "OG001", "value": "-9.3", "lowerLimit": "-16.3", "upperLimit": "-2.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Based on robust regression using M-estimation with terms for treatment and baseline FPG value.", "statisticalMethod": "Robust Regression", "paramType": "Estimate Difference", "paramValue": "-17.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.9", "ciUpperLimit": "-7.1"}]}, {"type": "PRIMARY", "title": "Number of Participants Who Experienced an Adverse Event", "description": "An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.", "populationDescription": "All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 26 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "248"}, {"groupId": "OG001", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "98"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "description": "An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.", "populationDescription": "All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 24 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "248"}, {"groupId": "OG001", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 26 weeks (including 14 days following the last dose of study medication).", "description": "All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study.", "seriousNumAffected": 7, "seriousNumAtRisk": 248, "otherNumAffected": 54, "otherNumAtRisk": 248}, {"id": "EG001", "title": "Placebo", "description": "Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for \u226510 weeks before and throughout the study.", "seriousNumAffected": 7, "seriousNumAtRisk": 249, "otherNumAffected": 40, "otherNumAtRisk": 249}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}]}, {"term": "Lung infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}]}, {"term": "Mastitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}]}, {"term": "Cervix carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}]}, {"term": "Thalamus haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}]}, {"term": "Vertebrobasilar insufficiency", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}]}], "otherEvents": [{"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 14, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 249}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 15, "numAffected": 15, "numAtRisk": 249}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 76, "numAffected": 35, "numAtRisk": 248}, {"groupId": "EG001", "numEvents": 28, "numAffected": 17, "numAtRisk": 249}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding the study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "D000005907", "term": "Gliclazide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M9018", "name": "Gliclazide", "asFound": "Boys", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}